Complete response to the combination of sintilimab and IBI305 for a patient with HBV-associated hepatocellular carcinoma with multiple lung metastasis

Dig Liver Dis. 2020 Jul;52(7):794-796. doi: 10.1016/j.dld.2020.04.005. Epub 2020 May 5.

Authors

Xiaohui Duan¹, Hui Zhang¹, Lixue Zhou¹, Bo Jiang¹, Xianhai Mao²

Affiliations

¹ Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, The First-affiliated Hospital of Hunan Normal University, No. 61 West Jiefang Road, Changsha 410005, China.
² Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, The First-affiliated Hospital of Hunan Normal University, No. 61 West Jiefang Road, Changsha 410005, China. Electronic address: maoxianhai@yahoo.net.

PMID: 32386943
DOI: 10.1016/j.dld.2020.04.005

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology*
Bevacizumab / pharmacology*
Carcinoma, Hepatocellular / drug therapy*
Carcinoma, Hepatocellular / pathology
Drug Therapy, Combination
Hepatitis B / complications
Humans
Liver Cirrhosis / complications
Liver Neoplasms / drug therapy*
Liver Neoplasms / pathology
Lung Neoplasms / drug therapy*
Lung Neoplasms / secondary
Male
Middle Aged
Remission Induction

Substances

Antibodies, Monoclonal, Humanized
Bevacizumab
sintilimab